Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

Lilly’s retatrutide, Pfizer’s berobenatide and Roche’s enicepatide posted weight-loss results that analysts say could shape each company’s obesity pipeline.

Summary by biopharmadive.com
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

2 Articles

PharmaphorumPharmaphorum
Center

ADA: Lilly's weight-loss reveal, and wannabes display wares

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

Read Full Article
biopharmadive.combiopharmadive.com
Center

ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news on Monday, June 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Diabetes icon

Diabetes

Obesity icon

Obesity

Novo Nordisk icon

Novo Nordisk

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal